|
Volumn 61, Issue 5, 2012, Pages 1070-1071
|
Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: Results of a feasibility questionnaire
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CISPLATIN;
MELANOMA ANTIGEN;
MELANOMA ANTIGENIC EPITOPE A3;
UNCLASSIFIED DRUG;
BLADDER CANCER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CYSTECTOMY;
FEASIBILITY STUDY;
HUMAN;
LETTER;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MUSCLE INVASIVE BLADDER CANCER;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
QUESTIONNAIRE;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II AS TOPIC;
CYSTECTOMY;
DISEASE-FREE SURVIVAL;
EUROPE;
FEMALE;
HUMANS;
MALE;
NEOADJUVANT THERAPY;
QUESTIONNAIRES;
SURVIVAL RATE;
TREATMENT OUTCOME;
URINARY BLADDER NEOPLASMS;
|
EID: 84859419726
PISSN: 03022838
EISSN: 18737560
Source Type: Journal
DOI: 10.1016/j.eururo.2012.01.039 Document Type: Letter |
Times cited : (76)
|
References (5)
|